

Published in final edited form as:

*Org Biomol Chem.* 2012 February 21; 10(7): 1424–1433. doi:10.1039/c1ob06602a.

## 1-(Fluoroalkylidene)-1,1-bisphosphonic Acids are Potent and Selective Inhibitors of the Enzymatic Activity of *Toxoplasma gondii* Farnesyl Pyrophosphate Synthase

Sergio H. Szajnman<sup>a</sup>, Valeria S. Rosso<sup>a,b</sup>, Leena Malayil<sup>b</sup>, Alyssa Smith<sup>b</sup>, Silvia N. J. Moreno<sup>b</sup>, Roberto Docampo<sup>b</sup>, and Juan B. Rodriguez<sup>a</sup>

<sup>a</sup>Departamento de Química Orgánica and UMYMFOR (CONICET–FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, C1428EHA, Buenos Aires, Argentina

<sup>b</sup>Center for Tropical and Emerging Global Diseases and Department of Cellular Biology, University of Georgia, Athens, Georgia, 30602, USA

### Abstract

$\alpha$ -Fluorinated-1,1-bisphosphonic acids derived from fatty acids were designed, synthesized and biologically evaluated against *Trypanosoma cruzi*, the etiologic agent of Chagas disease and against *Toxoplasma gondii*, the responsible agent of toxoplasmosis and also towards the target parasitic enzymes farnesyl pyrophosphate synthase of *T. cruzi* (TcFPPS) and *T. gondii* (TgFPPS), respectively. Interestingly, 1-fluorononylidene-1,1-bisphosphonic acid (compound **43**) has proven to be an extremely potent inhibitor of the enzymatic activity of TgFPPS at the low nanomolar range exhibiting an IC<sub>50</sub> of 30 nM. This compound was two-fold more potent than risedronate (IC<sub>50</sub> = 74 nM) taken as a positive control. This enzymatic activity was associated to a strong cell growth inhibition against tachyzoites of *T. gondii* having an IC<sub>50</sub> value of 2.7  $\mu$ M.

### Introduction

Bisphosphonates of general formula **1** are metabolically stable pyrophosphate (**2**) analogues in which a methylene group replaces the oxygen atom bridge between the two phosphorus atoms of the pyrophosphate moiety. Substitution at the carbon atom with different side chains has generated a large family of compounds.<sup>1</sup> Several bisphosphonates such as pamidronate (**3**), alendronate (**4**), risedronate (**5**), and ibandronate (**6**) are in clinical use for the treatment and prevention of osteoclast-mediated bone resorption associated with osteoporosis, Paget's disease, hypercalcemia, tumor bone metastases, and other bone diseases (Chart 1).<sup>2–4</sup> Bisphosphonates became compounds of pharmacological importance since calcification studies were done more than 40 years ago.<sup>5–7</sup>

Selective action on bone is based on the binding of the bisphosphonate moiety to the bone mineral.<sup>8</sup> It has been postulated that the acidocalcisomes are equivalent in composition to the bone mineral and that accumulation of bisphosphonates in these organelles, as they do in bone mineral, assists their antiparasitic action.<sup>8</sup> Bisphosphonates act by a mechanism that lead to osteoclast apoptosis.<sup>9</sup> The site of action of aminobisphosphonates has been narrowed down to the isoprenoid pathway and, more specifically, to an inhibition of protein prenylation.<sup>10</sup> Farnesyl pyrophosphate synthase (FPPS) constitutes the principal target of bisphosphonates.<sup>11–15</sup> This enzyme catalyzes the two mandatory biosynthetic steps to form

farnesyl pyrophosphate as indicated briefly in Scheme 1. Inhibition of the enzymatic activity of FPPS blocks farnesyl pyrophosphate and geranylgeranyl pyrophosphate formation that are required for the post-translational prenylation of small GTP-binding proteins, which are also GTPases such as Rab, Rho and Rac within osteoclasts.<sup>16</sup>

Besides their use in long-term treatments for different bone disorders, bisphosphonates additionally exhibit a wide range of biological actions such as stimulation of  $\gamma\delta$  T cells of the immune system,<sup>17</sup> antibacterial action,<sup>18</sup> herbicidal properties,<sup>19</sup> anticancer action,<sup>20–23</sup> as potent and selective inhibitors of the enzymatic activity of acid sphingomyelinase,<sup>24</sup> and, particularly, as antiparasitic agents.<sup>25–29</sup> Certainly, at the beginning, aminobisphosphonates have proven to be effective growth inhibitors of *T. cruzi* in *in vitro* and *in vivo* assays without toxicity to the host cells.<sup>8</sup> Inspired on this work, different bisphosphonates were found to be potent inhibitors of the proliferation of pathogenic trypanosomatids other than *T. cruzi*, such as *T. brucei rhodesiense*, *Leishmania donovani*, and *L. mexicana* and apicomplexan parasites such as *Toxoplasma gondii* and *Plasmodium falciparum*.<sup>27,28,30–36</sup> *In vivo* assays of bisphosphonates have shown that risedronate can significantly increase survival of *T. cruzi*-infected mice.<sup>37</sup> In view of the above results, it is possible to assume that bisphosphonates are potential candidates for chemotherapy of neglected infectious diseases. In addition, bisphosphonates have the advantage that their synthesis is straightforward and relatively inexpensive. It is reasonable to assume a low toxicity for bisphosphonate-containing drugs bearing in mind that many bisphosphonates are FDA-approved drugs for the long-term treatment of different bone disorders.<sup>38</sup>

Bisphosphonates derived from fatty acids have become interesting putative antiparasitic agents, especially 2-alkylaminoethyl derivatives, which were shown to be potent growth inhibitors against the clinically more relevant form of *T. cruzi* possessing IC<sub>50</sub> values at the nanomolar range against the target enzyme.<sup>31,32</sup> Compounds **10–12** arise as representative members of this type of bisphosphonates, which have proven to be by far more efficient than their parent drugs 1-hydroxy-, 1-alkyl-, and 1-amino-bisphosphonates as growth inhibitors of trypanosomatids (Chart 2).<sup>33–35</sup>

*T. cruzi*, which is the etiologic agent of American trypanosomiasis, has a complex life cycle involving blood-sucking Reduviid insects and mammals.<sup>39,40</sup> It multiplies in the insect gut as an epimastigote form and is spread as a non-dividing metacyclic trypomastigote from the insect feces by contamination of intact mucosa or wounds produced by the blood-sucking activity of the vector. In the mammalian host, the parasite proliferates intracellularly in the amastigote form and is subsequently released into the blood stream as a non-dividing trypomastigote.<sup>40</sup> On the other hand, the opportunistic pathogen *T. gondii* causes a broad spectrum of disease but most infections are asymptomatic.<sup>41</sup> This apicomplexan parasite has adopted an essential intracellular life style. The parasite actively penetrates host cells, sets up a privileged compartment in which it replicates and finally kills the cell.<sup>42</sup> There are two asexual forms that can cause disease in humans. The tachyzoite form can invade all types of cells and proliferate leading to host cell death. The bradyzoite form divides slowly and forms cysts in muscle and brain. The sexual cycle occurs in the superficial epithelium of the small intestine of members of the cat family. Oocysts, which are shed in feces of recently infected cats, remain in the upper soil horizon, where they may contaminate skin and may be ingested by hand-to-mouth transmission or on natural vegetables. Oocysts require at least 12 hours in order to complete sporulation, afterward they are infectious by mouth.<sup>43–46</sup> Chemotherapy for these neglected diseases is still deficient and based on old and empirically discovered drugs.<sup>47,48</sup> Therefore, there is a critical need to develop new safe drugs based on the knowledge of the biochemistry and physiology of these microorganisms.

## Rationale

The precise mechanism of action by which bisphosphonates inhibit the enzymatic activity of the target enzyme remains unsolved. The main members of 2-alkylaminoethyl bisphosphonates family were originally designed in order to maintain the ability to coordinate  $Mg^{2+}$  in a tridentate manner as 1-hydroxy- and 1-amino- derivatives do.<sup>32</sup> However, preliminary studies on the interaction of inhibitor **11** ( $IC_{50} = 58$  nM) with *Tc*FPPS based on the X-ray crystallographic structure of **11**-*Tc*FPPS have indicated that the nitrogen atom did not coordinate<sup>49</sup> the  $Mg^{2+}$  present at the active site of the target enzyme.<sup>50,51</sup> The tridentate coordination structure is circumvented to the hydroxyl groups bonded to the phosphorus atoms either for 2-alkylaminoethyl- or 1-hydroxy-1,1-bisphosphonates.<sup>52,53</sup> In addition, the X-ray structure of the complex risedronate-*Tc*FPPS indicated that the residue Asp250 forms a hydrogen bond with the hydroxyl group at the C-1 position of risedronate, event not possible with the 2-aminoalkyl derivatives.<sup>31,32,54</sup> In connection with the above ideas, it has been postulated that the presence of an electron withdrawing group at C-1 would enhance the ability to coordinate  $Ca^{2+}$  or  $Mg^{2+}$  in a tridentate manner.<sup>55-57</sup> Derivatives where the hydroxyl group is absent, that is, replaced by a hydrogen atom would coordinate in a bidentate manner. In fact, we have found that these analogues exhibited less potency as inhibitors towards the target enzyme than 1-hydroxy,<sup>34</sup> or 1-amino derivatives.<sup>35</sup> In addition, the influence of the hydroxyl group at C-1 on biological action in many bisphosphonates remains unclear; as a matter of fact there exists strong evidence available showing that the hydroxyl group at C-1 does not interact with  $Mg^{2+}$  at the active site of FPPS suggesting that this group would influence the capacity of the adjacent bisphosphonic moiety to chelate  $Mg^{2+}$  and to increase the  $pK_a$  of the *gem*-phosphonate functionality as well.

The introduction of a fluorine atom at the C-1 position of an 1-alkyl-1,1-bisphosphonate derivative such as **8** would seem of interest for a number of reasons: (a) isosteric replacement of hydroxyl groups or hydrogen atoms by fluorine atoms is usually employed in drug design based on the stability of the carbon-fluorine bond and the small atomic size that is benefit for molecular recognition;<sup>58</sup> (b) the presence of a fluorine atom would increase metabolic stability; (c) 1-fluoro-1,1-bisphosphonic acids would mimic quite well  $pK_a$  values of inorganic pyrophosphoric acid;<sup>59-62</sup> (d) these fluorine-containing bisphosphonic acid derivatives would increase acidity in at least one order of magnitude compared to conventional ones;<sup>63</sup> (e) it has been recently depicted that some fluorine-containing bisphosphonate having an aromatic ring at the side chain proven to be inhibitors of the enzymatic activity of human FPPS.<sup>64</sup>

## Results and Discussion

Formation of a carbon-fluorine bond can be envisioned through a reaction between an appropriate carbanion and an electrophilic fluorine donor such as Selectfluor (1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane bis(tetrafluoroborate), F-TEDABF<sub>4</sub>).<sup>65,66</sup> Sodium hydride has proven to be a good base to form a carbanion at the carbon bridge of a *gem*-phosphonate unit to react with Selectfluor<sup>TM</sup> to afford the desired monofluoro bisphosphonate derivatives.<sup>59,67,68</sup> There were two synthetic approaches to follow in order to access to our title compounds ( $\alpha$ -fluorinated bisphosphonates derived from fatty acids) taken **7-12** as reference structures (Chart 2): (a) to employ the already depicted tetraethyl 1-(fluoromethylidene)-1,1-bisphosphonate (compound **14**) as a common synthetic intermediate.<sup>67</sup> Alkylation of the respective enolate-type carbanion of **14**<sup>67</sup> by treatment with different alkyl halides followed by hydrolysis of the alkylated  $\alpha$ -fluoro-tetraethyl esters would yield the title compounds; (b) fluorination of the already depicted tetraethyl 1-alkyl-1,1-bisphosphonates<sup>34</sup> followed by hydrolysis of the resulting products

would be the latter approach. Although it would be possible to obtain the corresponding precursors of the title compounds from the simplest fluorine-containing intermediate (compound **14**) *via* an alkylation reaction as recently described,<sup>68</sup> however, the first route resulted to be impractical from the synthetic point of view, especially, this transformation was always associated to low reaction yields. The presence of a fluorine atom would increase the acidity of the hydrogen atom bonded at C-1 resulting in a weak and less reactive conjugate base. We succeeded in preparing the title drugs by using the second approach. Fluorination of compound **13** gave rise to **14** in 50% yield according to the literature.<sup>67</sup> We were able to fluorinate all the tetraethyl 1-alkyl-1,1-bisphosphonates in moderate but reproducible yields. Precursors (**16–25**) were obtained *via* either a hydrogenation reaction or a Michael addition on the already depicted tetraethyl ethenylidene bisphosphonate **15**.<sup>69</sup> Hydrolysis by treatment with bromotrimethylsilane in anhydrous methylene chloride followed by digestion with methanol afforded the desired 1-fluoro-1,1-bisphosphonic acids **35–44** (Scheme 2).

It is worth mentioning the difficulty to monitor the course of the reaction by t.l.c. These reactions, which involved compounds without chromophore groups and without sensitivity for universal revelators, should be followed by NMR.

Biological evaluation of the title compounds **35–44** was very surprising. All of these compounds were almost devoid of antiparasitic activity against the amastigote form of *T. cruzi*. Only compound **43** exhibited a marginal activity against intracellular amastigotes with 13% of growth inhibition at a concentration of 10  $\mu$ M. In addition, these results were consistent with inhibition studies towards the enzymatic activity of FPPS. Then, compounds **35–44** were devoid of activity against *T. cruzi* FPPS. These data were quite unexpected bearing in mind the inhibition action exhibited by lineal structurally related bisphosphonates.<sup>31–36</sup> On the other hand, these fluorine-containing bisphosphonic acids exhibited an extremely potent activity as inhibitors of the enzymatic activity of *T. gondii* FPPS.<sup>70</sup> In fact, relatively aliphatic long chain derivatives such as **40–44** showed an inhibitory action at the nanomolar level. Compounds **43** and **44** arose as main member of these drugs exhibiting an unusual potency against *Tg*FPPS possessing IC<sub>50</sub> values of 35 nM and 60 nM, respectively, and were more effective than risedronate (IC<sub>50</sub> = 74 nM) taken as positive control. This high selectivity towards *Tg*FPPS versus *Tc*FPPS might be understood by comparison of the amino acid sequence between both of these enzymes having less than 50% of identity.<sup>71</sup> Compound **43** was able to control growth of tachyzoites of *T. gondii* exhibiting an IC<sub>50</sub> value of 2.67  $\mu$ M (Table 1).

In summary, lineal  $\alpha$ -fluoro-1,1-bisphosphonic acids represent an interesting new family of bisphosphonates that was able to efficiently and selectively inhibit the enzymatic activity of *T. gondii* farnesyl pyrophosphate synthase. Particularly, compound **43**, which contains nine carbon atoms in the aliphatic chain, exhibited superior activity against *T. gondii* FPPS. As a result of this enzymatic action, this compound was able to impair tachyzoites of *T. gondii* growth. Structural variation in the aliphatic chain that includes the addition of conformational restriction tools will be considered in the near future in order to optimize its structure. Work aimed at exploiting the potential usefulness of these drugs is currently being pursued in our laboratory.

## Experimental Section

The glassware used in air and/or moisture sensitive reactions was flame-dried and carried out under a dry argon atmosphere. Unless otherwise noted, chemicals were commercially available and used without further purification. Solvents were distilled before use. Tetrahydrofuran and ethyl ether were distilled from sodium/benzophenone ketyl. Anhydrous

*N,N*-dimethylformamide was used as supplied from Aldrich. Tetraethyl methylenebisphosphonate and Selectfluor™ were purchased from Aldrich.

Nuclear magnetic resonance spectra were recorded using a Bruker AM-500 MHz or a Bruker AC-200 MHz spectrometers. Chemical shifts are reported in parts per million ( $\delta$ ) relative to tetramethylsilane. Coupling constants are reported in Hertz.  $^{13}\text{C}$ -NMR spectra were fully decoupled.  $^{31}\text{P}$ -NMR spectra were fully decoupled. Chemical shifts are reported in parts per million relative to phosphoric acid. Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet.

High resolution mass spectra were conducted using a Bruker micrOTOF-Q II spectrometer, which is a hybrid quadrupole time of flight mass spectrometer with MS/MS capability. Low-resolution mass spectra were obtained on a VG TRIO 2 or on a VG ZAB2-SEQ instruments in electron impact mode at 70 eV (direct inlet).

Melting points were determined using a Fisher-Johns apparatus and are uncorrected. IR spectra were recorded using a Nicolet Magna 550 spectrometer.

Column chromatography was performed with E. Merck silica gel (Kieselgel 60, 230–400 mesh). Analytical thin layer chromatography was performed employing 0.2 mm coated commercial silica gel plates (E. Merck, DC-Aluminum sheets, Kieselgel 60 F<sub>254</sub>).

Elemental analyses were performed by Atlantic Microlab, Norcross, Georgia, USA.

As judged from the homogeneity of the  $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{31}\text{P}$  NMR spectra of the title compounds **35–44** and HPLC analyses of the committed intermediates **14**, **16–18**, **20–25**, **26–34**, employing a Beckmann Ultrasphere ODS-2 column 5  $\mu\text{M}$ , 250  $\times$  10 mm eluting with acetonitrile–water (1:1) at 3.00 mL/min with a refractive index detector indicated a purity >97%.

#### Tetraethyl Ethylidene-1,1-bisphosphonate (16)

A solution of **15** (200 mg, 0.66 mmol) in ethyl acetate (10 mL) in the presence of 10% palladium on charcoal (30 mg) was treated with hydrogen under 3 atm at room temperature for 4 h. Then the reaction mixture was filtered and the solvent was evaporated to afford 190 mg (95% yield) of compound **16** as a colorless oil:  $R_f$  0.20 (EtOAc); IR (film,  $\text{cm}^{-1}$ ) 2985, 1645, 1251, 1022, 968, 819;  $^1\text{H}$  NMR (200.13 MHz,  $\text{CDCl}_3$ )  $\delta$  1.34 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.46 (dt,  $J = 17.4, 7.3$  Hz, 3H, H-2), 2.39 (tq,  $J = 30.8, 7.2$  Hz, 1H, H-1), 4.18 (m, 8H, H-1');  $^{13}\text{C}$  NMR (50.33 MHz,  $\text{CDCl}_3$ )  $\delta$  10.1 (t,  $J = 6.1$  Hz, C-2), 16.3 (d,  $J = 5.4$  Hz, C-2'), 31.0 (t,  $J = 136.3$  Hz, C-1), 62.46 (d,  $J = 6.8$ , C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  21.47; MS ( $m/z$ , relative intensity) 302 ( $\text{M}^+$ , 1), 275 (5), 247 (6), 191 (13), 165 (100).

#### Tetraethyl *n*-Propylidene-1,1-bisphosphonate (17)

A solution of **15** (200 mg, 0.66 mmol) in anhydrous tetrahydrofuran (10 mL) cooled at  $-78$  °C under argon atmosphere was treated with 1.6  $M$  of methyllithium in diethyl ether (0.4 mL). The reaction mixture was stirred at 0 °C for 2 h. the reaction was worked up by addition of an aqueous saturated solution of ammonium chloride (10 mL). The aqueous phase was extracted with chloroform (3  $\times$  10 mL). The combined organic layers were dried ( $\text{MgSO}_4$ ), and the solvent was evaporated. The residue was purified by column chromatography (silica gel) eluting with hexane–EtOAc (9:1) as eluent to give 83.2 mg (40% yield) of **17** as a colorless oil:  $R_f$  0.67 ( $\text{CH}_2\text{Cl}_2$ – $i$ -PrOH, 19:1); IR (film,  $\text{cm}^{-1}$ ) 3664, 2983, 1246, 1024, 962;  $^1\text{H}$  NMR (200.13 MHz,  $\text{CDCl}_3$ )  $\delta$  1.15 (t,  $J = 7.3$  Hz, 3H, H-3), 1.33 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.94 (m, 2H, H-2), 2.20 (tt,  $J = 23.9, 5.8$  Hz, 1H, H-1), 4.17 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  13.9 (dd,  $J = 6.3, 3.6$  Hz, C-2), 16.4 (dd,  $J =$

6.8, 3.4 Hz, C-2'), 19.1 (t,  $J = 5.5$  Hz, C-3), 38.2 (t,  $J = 133.5$  Hz, C-1), 62.7 (dd,  $J = 15.4$ , 6.4 Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ ) 23.84; MS ( $m/z$ , relative intensity) 316 ( $\text{M}^+$ , 1), 301 (11), 288 (17), 261 (14), 233 (15), 179 (100), 123 (45).

#### Tetraethyl *n*-Butylidene-1,1-bisphosphonate (18)

A solution of ethyl iodide (1.0 mL, 8.3 mmol) in anhydrous ethyl ether (10 mL) was added to magnesium turnings (204.8 mg, 8.3 mmol) in the presence of iodine (30 mg) under argon atmosphere. The reaction mixture was stirred at room temperature for 2 h. The resulting dark gray mixture was added slowly *via* cannula to a solution of **15** (500 mg, 1.6 mmol) in ethyl ether (10 mL) cooled at 0 °C. The mixture was stirred for 2 h and the reaction was quenched as depicted for the preparation of **17**. The residue was purified by column chromatography (silica gel) eluting with hexane–EtOAc (4:1) to afford 450 mg (85% yield) of **18** as a colorless oil:  $R_f$  0.72 (AcOEt– $\text{PrOH}$ – $\text{H}_2\text{O}$ , 6:3:1); IR (film,  $\text{cm}^{-1}$ ) 2980, 1394, 1245, 1165, 1033, 969;  $^1\text{H}$  NMR (200.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.89 (t,  $J = 7.3$  Hz, 3H, H-4), 1.31 (t,  $J = 6.9$  Hz, 12H, H-2'), 1.55 (m, 2H, H-3), 1.86 (m, 2H, H-2), 2.25 (tt,  $J = 24.1$ , 5.8 Hz, 1H, H-1), 4.14 (m, 8H, H-1');  $^{13}\text{C}$  NMR (50.33 MHz,  $\text{CDCl}_3$ )  $\delta$  13.7 (C-4), 16.3 (d,  $J = 6.8$  Hz, C-2'), 26.3 (t,  $J = 6.8$  Hz, C-2), 27.5 (t,  $J = 4.7$  Hz, C-3), 36.5 (t,  $J = 133.6$  Hz, C-1), 62.4 (d,  $J = 7.5$  Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  24.15; MS ( $m/z$ , relative intensity) 331 ( $[\text{M}+1]^+$ , 11), 301 (34), 288 (69), 261 (38), 193 (100), 165 (53), 152 (67), 137 (81). Anal. Calcd for  $\text{C}_{12}\text{H}_{28}\text{O}_6\text{P}_2\cdot\text{H}_2\text{O}$ : C 41.38, H 8.68; Found C 41.64, H 8.78.

#### Tetraethyl *n*-Pent-4-enylidene-1,1-bisphosphonate (19)

A solution of allyl chloride (0.4 mL, 5.0 mmol) in anhydrous tetrahydrofuran (10 mL) was added to magnesium turnings (121.5 mg, 5.0 mmol) in the presence of iodine (20 mg) under argon atmosphere. The mixture was stirred at room temperature for 2 h. Then the mixture was cooled at 0 °C and a solution of **15** (415.7 mg, 1.38 mmol) in tetrahydrofuran (5 mL) was added. The reaction mixture was treated as described for the preparation of **18**. The residue was purified by column chromatography (silica gel) eluting with hexane–EtOAc (1:1) to afford 150 mg (31% yield) of **19** as a colorless oil:  $R_f$  0.75 (AcOEt– $\text{PrOH}$ – $\text{H}_2\text{O}$ , 6:3:1); IR (film,  $\text{cm}^{-1}$ ) 2983, 2933, 2910, 1641, 1456, 1392, 1247, 1165, 1024, 972;  $^1\text{H}$  NMR (200.13 MHz,  $\text{CDCl}_3$ )  $\delta$  1.35 (t,  $J = 7.1$  Hz, 12H, H-2'), 2.19 (m, 5H, H-1, H-2, H-3); 4.19 (m, 8H, H-1'), 5.07 (m, 2H, H-5), 5.77 (ddt,  $J = 17.1$ , 10.2, 6.7 Hz, 1H, H-4);  $^{13}\text{C}$  NMR (50.33 MHz,  $\text{CDCl}_3$ )  $\delta$  16.3 (t,  $J = 6.8$  Hz, C-2'), 24.6 (t,  $J = 4.7$  Hz, C-2), 32.7 (t,  $J = 6.1$  Hz, C-3), 35.6 (t,  $J = 133.6$ , C-1), 62.5 (t,  $J = 6.8$  Hz, C-1'), 116.0 (C-5), 137.1 (C-4);  $^{31}\text{P}$  NMR  $\delta$  (202.45 MHz,  $\text{CDCl}_3$ ) 24.13; MS ( $m/z$ , relative intensity) 343 ( $[\text{M}+1]^+$ , 5), 288 (70), 261 (51), 233 (45), 205 (100), 152 (92), 109 (50).

#### Tetraethyl *n*-Pentylidene-1,1-bisphosphonate (20)

A solution of **19** (100 mg, 0.29 mmol) in ethyl acetate (10 mL) in the presence of 10% palladium on charcoal (30 mg) was treated as depicted for the preparation of compound **16** to give 85.1 mg (85% yield) of **20** as a colorless oil: IR (film,  $\text{cm}^{-1}$ ) 2960, 1662, 1471, 1247, 1024, 970;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.91 (t,  $J = 7.1$  Hz, 3H, H-5), 1.35 (t,  $J = 7.1$ , 12H, H-2'), 1.73 (m, 6H,  $-\text{CH}_2-$ ), 2.28 (tt,  $J = 24.1$ , 6.0 Hz, 1H, H-1) 4.17 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  13.7 (C-5), 16.3 (dd,  $J = 6.4$ , 2.3 Hz, C-2'), 22.4 (C-4), 25.2 (t,  $J = 5.0$  Hz, C-3), 31.2 (t,  $J = 6.4$  Hz, C-2), 36.7 (t,  $J = 133.4$  Hz, C-1), 62.4 (dd,  $J = 18.5$ , 6.7 Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  24.14; MS ( $m/z$ , relative intensity) 344 ( $\text{M}^+$ , 5), 301 (12), 288 (28), 207 (21), 152 (27), 57 (46), 41 (100).

#### Tetraethyl *n*-Hexylidene-1,1-bisphosphonate (21)

A solution of butyl chloride (0.42 mL, 4.3 mmol) in anhydrous tetrahydrofuran (10 mL) was treated with magnesium turnings (100 mg, 4.3 mmol) as depicted for the preparation of **19**.

Purification by column chromatography (silica gel) eluting with hexane–EtOAc (4:1) afforded 48 mg (33% yield) of **21** as a colorless oil:  $R_f$  0.20 (AcOEt–*i*-PrOH, 19:1); IR (film,  $\text{cm}^{-1}$ ) 2983, 1662, 1458, 1394, 1247, 1165, 1026, 972, 804;  $^1\text{H}$  NMR (200.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.88 (t,  $J = 6.6$  Hz, 3H, H-6), 1.33 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.25–1.4 (m, 4H, H-5, H-4) 1.59 (m, 2H, H-3), 1.91 (m, 2H, H-2), 2.26 (tt,  $J = 24.1, 5.8$  Hz, 1H, H-1), 4.17 (m, 8H, H-1');  $^{13}\text{C}$  NMR (50.33 MHz,  $\text{CDCl}_3$ )  $\delta$  13.9 (C-6), 16.3 (d,  $J = 5.4$  Hz, C-2'), 22.2 (C-5), 25.5 (t,  $J = 4.8$  Hz, C-3), 28.8 (t,  $J = 6.1$  Hz, C-2), 31.5 (C-4), 36.8 (t,  $J = 132.9$  Hz, C-1), 62.4 (t,  $J = 6.8$  Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  24.16; MS ( $m/z$ , relative intensity) 359 ( $[\text{M}+1]^+$ , 2), 301 (39), 288 (97), 261 (47), 233 (32), 221 (100), 165 (55), 152 (88). Anal. Calcd for  $\text{C}_{14}\text{H}_{32}\text{O}_6\text{P}_2 \cdot \text{H}_2\text{O}$ : C 44.68, H 9.11; Found C 44.97, H 8.71.

#### Tetraethyl *n*-Heptylidene-1,1-bisphosphonate (**22**)

A solution of *n*-pentyl bromide (0.62 mL, 5.0 mmol) in anhydrous tetrahydrofuran (10 mL) was treated with magnesium turnings (121.5 mg, 5.0 mmol) as described for the preparation of **19**. The residue was purified by column chromatography (silica gel) eluting with hexane–EtOAc (4:1) to yield 63.2 mg (17% yield) of **22** as a colorless oil:  $R_f$  0.23 (AcOEt–*i*-PrOH, 19:1); IR (film,  $\text{cm}^{-1}$ ) 2981, 2929, 2860, 1647, 1471, 1394, 1249, 1165, 1026, 970, 839, 792;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.88 (t,  $J = 6.9$  Hz, 3H, H-7), 1.34 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.30 (m, 6H,  $-\text{CH}_2-$ ), 1.55 (p,  $J = 7.4$  Hz, 2H, H-3), 1.91 (m, 2H, H-2), 2.27 (tt,  $J = 24.2, 6.0$  Hz, 1H, H-1), 4.17 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  14.0 (C-7), 16.4 (dd,  $J = 6.6, 3.0$  Hz, C-2'), 22.5 (C-6), 25.5 (t,  $J = 5.5$  Hz, C-3), 28.9 (C-4), 29.1 (t,  $J = 6.4$  Hz, C-2), 31.4 (C-5), 36.7 (t,  $J = 133.2$  Hz, C-1), 62.4 (dd,  $J = 18.5, 6.8$  Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  24.16; MS ( $m/z$ , relative intensity) 373 ( $[\text{M}+1]^+$ , 10), 301 (39), 288 (90), 261 (40), 235 (100), 207 (24), 189 (15), 179 (42), 165 (24), 152 (72), 137 (27), 125 (21). Anal. Calcd for  $\text{C}_{15}\text{H}_{34}\text{O}_6\text{P}_2$ : C 46.92, H 9.00; Found C 47.41, H 9.13.

#### Tetraethyl *n*-Octylidene-1,1-bisphosphonate (**23**)

A solution of *n*-hexyl bromide (0.70 mL, 5.0 mmol) in anhydrous tetrahydrofuran (10 mL) was treated with magnesium turnings (121.5 mg, 5.0 mmol) as depicted for the preparation of **19**. The product was purified by column chromatography (silica gel) eluting with hexane–EtOAc (2:3) to afford 112.6 mg (30% yield) of **23** as a colorless oil:  $R_f$  0.22 (AcOEt–*i*-PrOH, 19:1); IR (film,  $\text{cm}^{-1}$ ) 2927, 2856, 1652, 1465, 1394, 1247, 1165, 1026, 970, 856, 800;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.87 (t,  $J = 6.8$  Hz, 3H, H-8), 1.32 (m, 20H,  $-\text{CH}_2-$ , H-2'), 1.55 (m, 2H, H-3), 1.92 (m, 2H, H-2), 2.27 (tt,  $J = 24.2, 6.1$  Hz, 1H, H-1), 4.17 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  14.1 (C-8), 16.4 (dd,  $J = 5.9, 2.9$  Hz, C-2'), 22.6 (C-7), 25.5 (t,  $J = 5.4$  Hz, C-3), 28.9 (C-4), 29.1 (t,  $J = 6.3$  Hz, C-2), 29.3 (C-5), 31.7 (C-6), 36.8 (t,  $J = 133.5$  Hz, C-1) 62.4 (dd,  $J = 18.8, 6.7$  Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  24.15; MS ( $m/z$ , relative intensity) 387 ( $[\text{M}+1]^+$ , 3), 301 (42), 288 (100), 261 (37), 249 (96), 193 (30), 152 (67). Anal. Calcd for  $\text{C}_{16}\text{H}_{36}\text{O}_6\text{P}_2 \cdot 0.2\text{H}_2\text{O}$ : C 49.27, H 9.41; Found C 49.21, H 9.61.

#### Tetraethyl *n*-Nonylidene-1,1-bisphosphonate (**24**)

A solution of *n*-heptyl chloride (0.76 mL, 5.0 mmol) in anhydrous tetrahydrofuran (10 mL) was treated with magnesium turnings (121.5 mg, 5.0 mmol) as described for the preparation of **19**. Column chromatography purification eluting with hexane–EtOAc (9:1) afforded 160 mg (40% yield) of **24** as a colorless oil:  $R_f$  0.28 (AcOEt–*i*-PrOH, 19:1); IR (film,  $\text{cm}^{-1}$ ) 2927, 2856, 1647, 1467, 1444, 1392, 1251, 1165, 1024, 970, 835, 794;  $^1\text{H}$  NMR (200.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.87 (t,  $J = 6.4$  Hz, 3H, H-9), 1.32 (m, 10H,  $-\text{CH}_2-$ ), 1.34 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.56 (m, 2H, H-3), 1.90 (m, 2H, H-2), 2.26 (tt,  $J = 23.9, 6.0$  Hz, 1H, H-1), 4.17 (m, 8H, H-1');  $^{13}\text{C}$  NMR (50.33 MHz,  $\text{CDCl}_3$ )  $\delta$  14.0 (C-9), 16.4 (d,  $J = 6.8$  Hz, C-2'), 22.6

(C-8), 25.5 (t,  $J = 5.4$  Hz, C-3), 25.7 (C-4), 29.1 (t,  $J = 6.5$  Hz, C-2), 29.2 (C-5),\* 29.3 (C-6),\* 31.8 (C-7), 36.7 (t,  $J = 133.6$  Hz, C-1), 62.4 (t,  $J = 7.5$  Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  24.15; MS ( $m/z$ , relative intensity) 401 ( $[\text{M}+1]^+$ , 28), 301 (38), 288 (100), 263 (90), 261 (35), 152 (58). Anal. Calcd for  $\text{C}_{17}\text{H}_{38}\text{O}_6\text{P}_2\cdot\text{H}_2\text{O}$ : C 48.80, H 9.64; Found C 48.48, H 9.57.

#### Tetraethyl *n*-Decylidene-1,1-bisphosphonate (25)

A solution of *n*-octyl chloride (0.85 mL, 5.0 mmol) in anhydrous tetrahydrofuran (10 mL) was treated with magnesium turnings (121.5 mg, 5.0 mmol) as described for the preparation of **19**. The product was purified by column chromatography (silica gel) eluting with hexane–EtOAc (19:1) to afford 186.3 mg (45% yield) of **25** as a colorless oil:  $R_f$  0.12 (hexane–EtOAc, 4:1); IR (film,  $\text{cm}^{-1}$ ): 2979, 2929, 2873, 1458, 1392, 1251, 1165, 1026, 968, 813;  $^1\text{H}$  NMR (200.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.89 (t,  $J = 6.7$  Hz, 3H, H-10), 1.28 (m, 12H,  $-\text{CH}_2-$ ), 1.34 (t,  $J = 6.7$  Hz, 12H, H-2'), 1.51 (m, 2H, H-3), 1.89 (m, 2H, H-2), 2.22 (tt,  $J = 24.3, 5.8$  Hz, 1H, H-1), 4.17 (m, 8H, H-1');  $^{13}\text{C}$  NMR (50.33 MHz,  $\text{CDCl}_3$ )  $\delta$  14.0 (C-10), 16.3 (d,  $J = 6.8$  Hz, C-2'), 23.0 (C-9), 21.7 (t,  $J = 5.4$  Hz, C-3), 29.1 (t,  $J = 6.2$  Hz, C-2), 29.5 (C-4, C-7), 28.7 (C-5, C-6), 32.4 (C-8), 37.0 (t,  $J = 133.6$  Hz, C-1), 62.3 (t,  $J = 6.1$  Hz, C-1');  $^{31}\text{P}$  NMR (202.45 MHz,  $\text{CDCl}_3$ )  $\delta$  24.15; MS ( $m/z$ , relative intensity) 415 ( $[\text{M}+1]^+$ , 20), 385 (5), 371 (5), 357 (6), 315 (10), 301 (28), 288 (100), 277 (67), 261 (32), 165 (23), 152 (49). Anal. Calcd for  $\text{C}_{18}\text{H}_{40}\text{O}_6\text{P}_2\cdot\text{H}_2\text{O}$ : C 49.99, H 9.79; Found C 50.39, H 9.76.

#### Fluorination Reaction. General procedure

Sodium hydride (10.5 mmol, 60% in mineral oil) was washed with anhydrous hexane under an argon atmosphere, and then anhydrous tetrahydrofuran (190 mL) was added. The suspension was cooled at 0 °C, and, in independent experiments, each tetraethyl 1-alkyl-1,1-bisphosphonates such as **14**, **16–18**, **20–25** (10.0 mmol) in anhydrous tetrahydrofuran (10 mL) were added. The solution was stirred at 0 °C for 15 min, then, the mixture was allowed to reach room temperature and was stirred for 60 min. The mixture was cooled at 0 °C and Selectfluor™ (12.5 mmol) was added in one portion followed by addition of anhydrous *N,N*-dimethylformamide (3.5 mL). The reaction mixture was allowed to reach room temperature and was stirred for 4 h. The mixture was partitioned between methylene chloride (30 mL) and an aqueous saturated solution of ammonium chloride (30 mL). The aqueous phase was extracted with methylene chloride (2 × 30 mL). The combined organic layers were washed with water (2 × 30 mL), dried ( $\text{MgSO}_4$ ), and the solvent was evaporated. The residue was purified by column chromatography eluting with mixtures of (EtOAc– $\text{CH}_3\text{OH}$ ) in a ratio indicated in each case to afford the corresponding 1-fluoro tetraethyl ester derivative (compounds **14**, **26–34**).

#### Tetraethyl 1-(Fluoromethylidene)-1,1-bisphosphonate (14)

50% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2987, 2935, 2914, 1479, 1444, 1394, 1371, 1261, 1164, 1028, 981, 869, 794;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  1.38 (dt,  $J = 7.1, 1.4$  Hz, 12H, H-2'), 4.29 (m, 8H, H-1'), 5.01 (dt,  $J = 45.9, 13.9$  Hz, H-1);  $^{13}\text{C}$  NMR (50.3 MHz,  $\text{CDCl}_3$ )  $\delta$  15.8 (C-2'), 63.9 (dt,  $J = 17.7, 2.7$  Hz, Hz, C-1'), 82.78 (dt,  $J = 192.0, 157.1$  Hz, C-1),  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  11.08 (d,  $J = 74.6$  Hz); HRMS (ESI) Calcd. for ( $\text{C}_9\text{H}_{21}\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{Na}]^+$ : 329.0695; found 329.0697.

#### Tetraethyl 1-(Fluoroethylidene)-1,1-bisphosphonate (26)

43% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2984, 2935, 2874, 1445, 1393, 1369, 1256, 1165, 1024, 970, 845, 816, 793, 536;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  1.37 (d,  $J = 7.1$  Hz, 12H, H-2'), 1.83 (dt,  $J = 25.7, 15.4$  Hz, 3H, H-2), 4.28 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  16.4 (dd,  $J = 7.1, 2.9$  Hz, C-2), 19.1 (d,  $J = 20.9$  Hz, C-2'), 64.0 (dt,  $J = 28.0, 3.2$



Hz, C-1'), 93.0 (dt,  $J = 183.9, 160.5$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  14.92 (d,  $J = 72.1$  Hz). HRMS (ESI) Calcd. for  $(\text{C}_{10}\text{H}_{24}\text{O}_6\text{P}_2\text{F})$   $[\text{M}+\text{H}]^+$ : 321.1032; found 321.1022.

#### Tetraethyl 1-(Fluoro-*n*-propylidene)-1,1-bisphosphonate (27)

36% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2981, 2933, 1444, 1394, 1369, 1263, 1164, 1022, 972, 784, 769;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  1.17 (t,  $J = \text{Hz}$ , 3H, H-3), 1.37 (t,  $J = \text{Hz}$ , 12H, H-2'), 2.24 (m, 2H, H-2), 4.29 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  7.8 (dd,  $J = 12.7, 4.6$  Hz), 16.4 (dt,  $J = 5.9, 3.0$  Hz), 26.5 (d,  $J = 20.9$  Hz, C-2'), 63.8 (dt,  $J = 28.2, 3.2$  Hz, C-1');  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  15.00 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for  $(\text{C}_{11}\text{H}_{25}\text{FO}_6\text{P}_2\text{Na})$   $[\text{M}+\text{Na}]^+$ : 357.1008; Found 357.1013.

#### Tetraethyl 1-(Fluoro-*n*-butylidene)-1,1-bisphosphonate (28)

47% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2981, 2935, 2875, 1649, 1444, 1392, 1369, 1261, 1164, 1022, 972, 794, 746;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.97 (t,  $J = 7.3$  Hz, 3H, H-4), 1.38 (t,  $J = 7.0$  Hz, 12H, H-2'), 1.68 (m, 2H, H-3), 2.14 (dtt,  $J = 47.0, 15.1, 8.6$  Hz, 2H, H-2), 4.25 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  14.52 (C-4), 16.43 (p,  $J = 2.9$  Hz, C-2'), 16.54 (q,  $J = 5.4$  Hz), 35.29 (d,  $J = 20.0$  Hz), 63.87 (dt,  $J = 27.4, 2.4$  Hz, C-1'), 95.86 (dt,  $J = 187.3, 156.2$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  14.52 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for  $(\text{C}_{12}\text{H}_{28}\text{FO}_6\text{P}_2)$   $[\text{M}+\text{H}]^+$ : 349.1345; Found: 349.1348.

#### Tetraethyl 1-(Fluoro-*n*-pentylidene)-1,1-bisphosphonate (29)

49% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2964, 2934, 2874, 1445, 1393, 1261, 1165, 1024, 975, 797, 540;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.93 (t,  $J = 7.4$  Hz, 3H, H-5), 1.37 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.70 (br s, 2H), 2.17 (m, 2H, H-2), 4.27 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  13.76, 14.43 (q,  $J = 2.9$  Hz, C-2'), 23.09, 25.04 (t,  $J = 5.5$  Hz), 32.99 (d,  $J = 20.1$  Hz), 63.86 (dt,  $J = 27.2, 3.2$  Hz, C-1');  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  15.79 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for  $(\text{C}_{13}\text{H}_{30}\text{O}_6\text{P}_2\text{F})$   $[\text{M}+\text{H}]^+$ : 363.1502; found 363.1508.

#### Tetraethyl 1-(Fluoro-*n*-hexylidene)-1,1-bisphosphonate (30)

57% Yield; Colorless oil;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.90 (t,  $J = 7.1$  Hz, 3H, H-5), 1.30 (m, 8H, H-4, H-5, H-6, H-7), 1.37 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.64 (p,  $J = 7.2$  Hz, 2H, H-3), 2.15 (dt,  $J = 22.3, 15.3$  Hz, H-2), 4.28 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  13.88 (C-6), 16.39 (p,  $J = 3.0$  Hz, C-2'), 22.23 (C-5), 22.57 (q,  $J = 5.4$  Hz, C-3), 32.09 (C-4), 33.17 (d,  $J = 20.0$  Hz, C-2), 63.81 (dt,  $J = 27.2, 3.2$  Hz, C-1'), 95.85 (dt,  $J = 187.1, 156.2$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  15.02 (d,  $J = 74.6$  Hz).

#### Tetraethyl 1-(Fluoro-*n*-heptylidene)-1,1-bisphosphonate (31)

35% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2984, 2961, 2932, 2872, 2858, 1456, 1393, 1369, 1261, 1164, 1022, 976, 794, 576;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.88 (t,  $J = 6.9$  Hz, 3H, H-7), 1.30 (m, 6H, H-4, H-5, H-6), 1.36 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.64 (m, 2H, H-3), 2.15 (m, 2H, H-2), 4.26 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  13.98 (C-7), 16.38 (p,  $J = 2.7$  Hz, C-2'), 22.45 (C-6), 22.84 (q,  $J = 5.4$  Hz, C-3), 29.59 (C-5), 31.38 (C-4), 33.21 (d,  $J = 20.1$  Hz, C-2), 63.78 (dt,  $J = 27.2, 3.2$  Hz, C-1'), 95.84 (dt,  $J = 188.0, 156.2$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  14.76 (d,  $J = 75.1$  Hz). Calcd. for  $(\text{C}_{15}\text{H}_{34}\text{FO}_6\text{P}_2)$   $[\text{M}+\text{Na}]^+$ : 413.1634; found: 413.1635.

#### Tetraethyl 1-(Fluoro-*n*-octylidene)-1,1-bisphosphonate (32)

48% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2982, 2959, 2930, 2858, 2358, 1452, 1393, 1258, 1165, 1026, 970, 797, 580, 538;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.90 (t,  $J = 7.0$  Hz, 3H, H-8), 1.30 (t,  $J = 7.1$  Hz, 12H, H-2'), 2.15 (dtt,  $J = 23.8, 15.3, 8.4$  Hz, 2H, H-2), 4.27 (m,

8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  14.06 (C-8), 16.46 (p,  $J = 3.1$  Hz, C-2'), 22.59 (C-7), 22.96 (q,  $J = 5.3$  Hz, C-3), 28.90 (C-6), 29.93 (C-5), 31.70 (C-4), 33.27 (d,  $J = 19.8$  Hz, C-2), 63.87 (dt,  $J = 27.3, 2.8$  Hz, C-1'), 95.84 (dt,  $J = 188.0, 156.2$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  14.58 (d,  $J = 74.6$  Hz). (F8OEt) HRMS (ESI) Calcd. for ( $\text{C}_{16}\text{H}_{36}\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{H}]^+$ : 405.1971; found 405.1977.

#### Tetraethyl 1-(Fluoro-*n*-nonylidene)-1,1-bisphosphonate (33)

24% Yield; Colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2981, 2959, 2928, 2856, 1467, 1392, 1369, 1261, 1163, 1024, 974, 797, 663, 577, 540;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  0.88 (t,  $J = 7.0$  Hz, 3H, H-9), 1.30 (m, 10H), 1.37 (t,  $J = 7.1$  Hz, 12H, H-2'), 1.64 (p,  $J = 7.3$  Hz, 2H, H-3), 2.15 (dt,  $J = 47.3, 15.3, 8.3$  Hz, 2H, H-2), 4.27 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  14.06 (C-9), 16.43 (p,  $J = 2.7$  Hz, C-2'), 22.62 (C-8), 22.93 (q,  $J = 5.4$  Hz, C-3), 29.15 (C-7), 29.19 (C-6), 29.98 (C-5), 31.80 (C-4), 33.25 (d,  $J = 20.1$  Hz, C-2), 63.83 (dt,  $J = 27.3, 2.7$  Hz, C-1');  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  15.01 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for ( $\text{C}_{17}\text{H}_{38}\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{H}]^+$ : 419.2128; found 419.2131.

#### Tetraethyl 1-(Fluoro-*n*-decylidene)-1,1-bisphosphonate (34)

33% Yield; colorless oil; IR (film,  $\text{cm}^{-1}$ ) 2982, 2961, 2926, 2856, 1468, 1450, 1393, 1369, 1261, 1165, 1024, 976, 797, 663, 540;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.90 (t,  $J = 6.9$  Hz, 3H, H-10), 1.32 (m, 6H,  $\text{CH}_2$ ), 1.39 (t,  $J = 7.1$  Hz, 8H, H-2'), 1.63 (m, 2H, H-3), 2.12 (dt,  $J = 47.4, 15.4, 8.4$  Hz, 2H, H-2), 4.26 (m, 8H, H-1');  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  14.1 (C-10), 16.5 (p,  $J = 2.9$  Hz, C-2'), 22.6 (C-9), 23.0 (q,  $J = 5.5$  Hz, C-3), 29.2 (C-6), 29.5 (C-7), 30.0 (C-5), 31.9 (C-4), 33.3 (d,  $J = 19.6$  Hz, C-2), 63.9 (dt,  $J = 27.9, 3.2$  Hz, C-1');  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  14.78 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for ( $\text{C}_{10}\text{H}_{39}\text{O}_6\text{P}_2\text{FNa}$ )  $[\text{M}+\text{Na}]^+$ : 455.2104; found 455.2105.

### Silylation/Methanolysis. General procedure

To a solution of the resulting tetraethyl ester (**14**, **26–34**; 1 equivalent) in anhydrous methylene chloride was added dropwise trimethylsilyl bromide (10 equivalents) in an argon atmosphere. The reaction mixture was stirred at room temperature for 48 h. After cooling at 0 °C, anhydrous methanol (10 mL) was added, and the resulting mixture was allowed to reach room temperature. The solution was then concentrated under reduced pressure. The residue was dissolved in dry methanol (10 mL) and subsequently concentrated under reduced pressure twice. The solvent was evaporated and the residue was purified by reverse phase column chromatography or crystallized from ethanol–water to afford the title compounds **35–44**.

#### 1-(Fluoromethylene)-1,1-bisphosphonic acid (35)

93% Yield; syrup;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.78 (dt,  $J = 45.1, 12.7$  Hz, H-1);  $^{13}\text{C}$  NMR (50.3 MHz,  $\text{DMSO}-d_6$ )  $\delta$  86.2 (dt,  $J = 185.3, 148.4$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{D}_2\text{O}$ )  $\delta$  10.06 (d,  $J = 64.7$  Hz); HRMS (ESI) Calcd. for ( $\text{CH}_5\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{Na}]^+$ : 216.9443; found 216.9438.

#### 1-(Fluoroethylidene)-1,1-bisphosphonic acid (36)

96% Yield; syrup; IR (KBr,  $\text{cm}^{-1}$ ) 3406, 2985, 2929, 2866, 1731, 1681, 1400, 1220, 1024, 935, 825, 767, 628, 518;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  1.39 (dt,  $J = 27.3, 14.8$  Hz, H-2);  $^{13}\text{C}$  NMR (125 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  19.8 (d,  $J = 20.9$  Hz, C-2), 94.21 (dt,  $J = 180.3, 152.8$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{D}_2\text{O}$ )  $\delta$  12.24 (d,  $J = 69.7$  Hz). HRMS (ESI) Calcd. for ( $\text{C}_2\text{H}_8\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{H}]^+$ : 208.9780; found 208.9780.

**1-(Fluoro-*n*-propylidene)-1,1-bisphosphonic acid (37)**

96% Yield; syrup; IR (KBr,  $\text{cm}^{-1}$ ) 3604, 2995, 2950, 2931, 2314, 1728, 1703, 1467, 1205, 1022, 956, 763, 626;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  1.01 (t,  $J = 7.5$  Hz, 3H, H-3), 2.07 (dt,  $J = 45.7, 15.0, 7.7$  Hz, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{DMSO}-d_6$ )  $\delta$  9.41 (d,  $J = 5.4$  Hz, C-3), 27.18 (d,  $J = 20.9$  Hz, C-2), 97.86 (dt,  $J = 180.7, 141.2$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{D}_2\text{O}$ )  $\delta$  14.16 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for ( $\text{C}_3\text{H}_9\text{FO}_6\text{P}_2\text{Na}$ )  $[\text{M}+\text{Na}]^+$ : 244.9756; Found: 244.9748.

**1-(Fluoro-*n*-butylidene)-1,1-bisphosphonic acid (38)**

90% Yield; syrup;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CDCl}_3$ )  $\delta$  0.85 (t,  $J = 7.3$  Hz, 3H, H-4), 1.55 (m, 2H, H-3), 1.96 (m, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CDCl}_3$ )  $\delta$  14.63, 16.62 (q,  $J = 5.6$  Hz), 34.51 (d,  $J = 19.5$  Hz), 94.73 (dt,  $J = 184.1, 146.7$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CDCl}_3$ )  $\delta$  13.20 (d,  $J = 72.1$  Hz); HRMS (ESI) Calcd. for ( $\text{C}_4\text{H}_{11}\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{Na}]^+$ : 258.9913; found 258.9903.

**1-(Fluoro-*n*-pentylidene)-1,1-bisphosphonic acid (39)**

93% Yield; syrup; (KBr,  $\text{cm}^{-1}$ ) 3155, 2962, 2875, 1653, 1468, 1402, 1213, 1022, 943, 660, 520;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  0.94 (t,  $J = 7.3$  Hz, 3H, H-5), 1.36 (1.35 (sext,  $J = 7.4$  Hz, 2H, H-4), 1.68 (m, 2H, H-3), 2.17 (m, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{D}_2\text{O}$ )  $\delta$  13.01 (C-5), 22.59 (C-4), 25.19 (q,  $J = 5.1$  Hz, C-3), 32.13 (d,  $J = 19.1$  Hz, C-2) HRMS (ESI) Calcd. for ( $\text{C}_5\text{H}_{13}\text{O}_6\text{P}_2\text{FNa}$ )  $[\text{M}+\text{Na}]^+$ : 273.0069; found 273.0069.

**1-(Fluoro-*n*-hexylidene)-1,1-bisphosphonic acid (40)**

95% Yield; Syrup; (KBr,  $\text{cm}^{-1}$ ) 3612, 2961, 2924, 2872, 1685, 1462, 1198, 1177, 1140, 1028, 1020, 943, 659, 513;  $^1\text{H}$  NMR (500.13 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  0.90 (t,  $J = 6.9$  Hz, 3H, H-6), 1.34 (m, 4H, H-4, H-5), 1.68 (m, 2H, H-3), 2.15 (m, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  14.39 (C-6), 23.40 (C-5), 24.07 (q,  $J = 4.5$  Hz, C-3), 33.49 (C-4), 33.91 (d,  $J = 20.0$  Hz, C-2);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  14.55 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for ( $\text{C}_6\text{H}_{16}\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{H}]^+$ : 265.0406; found 265.0401.

**1-(Fluoro-*n*-heptylidene)-1,1-bisphosphonic acid (41)**

99% Yield; syrup; IR (KBr,  $\text{cm}^{-1}$ ) 3611, 2951, 2937, 2916, 2856, 2246, 1712, 1470, 1200, 1120, 1049, 955, 895, 878, 717, 667, 561, 460;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  0.77 (t,  $J = 7.1$  Hz, 3H, H-7), 1.34 (m, 6H, H-4, H-5, H-6), 1.51 (p,  $J = 7.6$  Hz, 2H, H-3), 2.15 (m, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{D}_2\text{O}$ )  $\delta$  13.30 (C-7), 21.8645 (C-6), 22.98 (q,  $J = 5.5$  Hz, C-3), 29.00 (C-5), 30.73 (C-4), 33.42 (d,  $J = 19.7$  Hz, C-2), 95.89 (dt,  $J = 181.4, 144.5$  Hz, C-1);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{D}_2\text{O}$ )  $\delta$  14.76 (d,  $J = 72.15$  Hz). HRMS (ESI) Calcd. for ( $\text{C}_7\text{H}_{17}\text{O}_6\text{P}_2\text{FNa}$ )  $[\text{M}+\text{Na}]^+$ : 301.0382; found 301.0390.

**1-(Fluoro-*n*-octylidene)-1,1-bisphosphonic acid (42)**

97% Yield; syrup; IR (KBr,  $\text{cm}^{-1}$ ) 3570, 2959, 2928, 2858, 1695, 1468, 1211, 1016, 960, 662, 567, 513;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  0.76 (t,  $J = 6.9$  Hz, 3H, H-8), 1.20 (m, 8H, H-4, H-5, H-6, H-7), 1.51 (p,  $J = 7.9$  Hz, 2H, H-3), 2.01 (m, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{D}_2\text{O}$ )  $\delta$  13.35 (C-8), 21.95 (C-7), 23.07 (q,  $J = 5.3$  Hz, C-3), 28.13 (C-6), 29.32 (C-5), 31.00 (C-4), 33.42 (d,  $J = 18.8$  Hz, C-2);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{D}_2\text{O}$ )  $\delta$  14.2 (d,  $J = 74.6$  Hz). HRMS (ESI) Calcd. for ( $\text{C}_8\text{H}_{20}\text{O}_6\text{P}_2\text{F}$ )  $[\text{M}+\text{H}]^+$ : 293.0719; found 293.0720.

**1-(Fluoro-*n*-nonylidene)-1,1-bisphosphonic acid (43)**

96% Yield; white solid; mp 119 °C; IR (KBr,  $\text{cm}^{-1}$ ) 3608, 2950, 2916, 2852, 1469, 1201, 1126, 1053, 1028, 956, 667, 561, 462;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  0.74 (t,  $J = 6.9$  Hz,

3H, H-9), 1.18 (m, 10H, H-4, H-5, H-6, H-7, H-8), 1.49 (m, 2H, H-3), 1.98 (m, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{D}_2\text{O}$ )  $\delta$  13.4 (C-9), 22.0 (C-8), 28.4 (C-7), 28.5 (C-6), 29.5 (C-5), 31.1 (C-4), 32.4 (d,  $J=20.4$  Hz, C-3), 34.9 (C-2);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{D}_2\text{O}$ )  $\delta$  13.95 (d,  $J=69.8$  Hz). HRMS (ESI) Calcd. for  $(\text{C}_9\text{H}_{21}\text{O}_6\text{P}_2\text{FNa})$   $[\text{M}+\text{Na}]^+$ : 329.0695; found 329.0686.

### 1-(Fluoro-*n*-decylidene)-1,1-bisphosphonic acid (44)

94% Yield; white solid; mp 58–59 °C; IR (KBr,  $\text{cm}^{-1}$ ) 3626, 2920, 28532, 1470, 1195, 1144, 1080, 1032, 947, 717, 665, 563, 514, 457;  $^1\text{H}$  NMR (500.13 MHz,  $\text{D}_2\text{O}$ )  $\delta$  0.70 (t,  $J=7.0$  Hz, 3H, H-10), 1.13 (m, 8H,  $\text{CH}_2$ ), 1.17 (m, 4H,  $\text{CH}_2$ ), 1.48 (p,  $J=7.1$  Hz, 2H, H-3), 2.01 (m, 2H, H-2);  $^{13}\text{C}$  NMR (125.77 MHz,  $\text{D}_2\text{O}$ )  $\delta$  13.37 (C-10), 22.02 (C-9), 23.14 (q,  $J=5.4$  Hz, C-3), 28.42 (C-8), 28.46 (C-7), 28.66 (C-6), 29.39 (C-5), 31.13 (C-4), 33.41 (d,  $J=20.0$  Hz, C-2);  $^{31}\text{P}$  NMR (202.46 MHz,  $\text{D}_2\text{O}$ )  $\delta$  14.22 (d,  $J=71.6$  Hz). HRMS (ESI) Calcd. for  $(\text{C}_{10}\text{H}_{24}\text{O}_6\text{P}_2\text{F})$   $[\text{M}+\text{H}]^+$ : 321.1032; found 321.1032.

## Drug Screening

### *T. cruzi* amastigotes assays

Gamma-irradiated (2,000 Rads) Vero cells ( $3.4 \times 10^4$  cells/well) were seeded in 96 well plates (black, clear bottom plates from Greiner Bio-One) in 100  $\mu\text{L}$  RPMI media (Sigma) with 10 % FBS. Plates were incubated overnight at 35 °C and 7 %  $\text{CO}_2$ . After overnight incubation, Vero cells were challenged with  $3.4 \times 10^5$  trypomastigotes/well (CL strain overexpressing a tdTomato red fluorescent protein) in 50  $\mu\text{L}$  volume and incubated for 5 h at 35 °C and 7 %  $\text{CO}_2$ . After infection, cells were washed once with Hanks solution (150  $\mu\text{L}$ /well) to eliminate any extracellular parasites and compounds were added in serial dilutions in RPMI media in 150  $\mu\text{L}$  volumes. Each dilution was tested in quadruplicate. Each plate also contained controls with host cells and no parasites (for background check), controls with two representative drug dilutions and no parasites (for cytotoxicity assays), and controls with parasites and no drugs (positive control). For each plate, benznidazole was also used as a positive control at 3.5 and 1.5  $\mu\text{M}$ . After drug addition, plates were incubated at 35 °C and 7 %  $\text{CO}_2$ . At day 3 post-infection, plates were assayed for fluorescence.<sup>72</sup>  $\text{IC}_{50}$  values were determined by non-linear regression analysis using SigmaPlot.

### *T. gondii* tachyzoites assays

Experiments on *T. gondii* tachyzoites were carried out as described previously<sup>73</sup> using *T. gondii* tachyzoites expressing red fluorescence protein.<sup>74</sup> Cells were routinely maintained in hTerT cells grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% fetal bovine serum, 2 mM glutamine, 1 mM pyruvate, at 37 °C in a humid 5%  $\text{CO}_2$  atmosphere. Confluent monolayers grown in 96-well black plates with optical bottoms (Falcon/Becton-Dickinson, Franklin Lakes, NJ) were used and drugs dissolved in the same medium and serially diluted in the plates. Freshly isolated tachyzoites were filtered through a 3  $\mu\text{m}$  filter and passed through a 22 gauge needle, before use. The cultures were inoculated with  $10^4$  tachyzoites/well in the same media. The plates were incubated at 37 °C and read daily in a Molecular Devices fluorescence plate reader. To preserve sterility the plates were read with covered lids, and both excitation (510 nm) and emission (540 nm) were read from the bottom.<sup>75</sup> For the calculation of the  $\text{IC}_{50}$ , the percent of growth inhibition was plotted as a function of drug concentration by fitting the values to the function:  $I = I_{\text{max}} C / (\text{IC}_{50} + C)$ , where  $I$  is the percent inhibition,  $I_{\text{max}} = 100\%$  inhibition,  $C$  is the concentration of the inhibitor, and  $\text{IC}_{50}$  is the concentration for 50% growth inhibition.

## TcFPPS and TgFPPS Assays and Product Analysis

For TcFPPS<sup>76–78</sup> 100  $\mu$ L of assay buffer (10 mM Hepes, pH 7.4, 1 mM MgCl<sub>2</sub>, 2 mM dithiothreitol, 4.7  $\mu$ M [4-<sup>14</sup>C]IPP (10  $\mu$ Ci/ $\mu$ mol)), and 55  $\mu$ M DMAPP were prewarmed to 37 °C. The assay was initiated by the addition of recombinant protein (10–20 ng). The assay was allowed to proceed for 30 min at 37 °C and was quenched by the addition of 6 M HCl (10  $\mu$ L). The reactions were made alkaline with 6.0 M NaOH (15  $\mu$ L), diluted in water (0.7 mL), and extracted with hexane (1 mL). The hexane solution was washed with water and transferred to a scintillation vial for counting. One unit of enzyme activity was defined as the activity required to incorporate 1 nmol of [4-<sup>14</sup>C]IPP into [14-<sup>14</sup>C]FPP in 1 min.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

This work was supported by grants from the National Research Council of Argentina (PIP 1888), ANPCyT (PICT 2008 #1690), and the Universidad de Buenos Aires (X-191) to J.B.R., and Bunge & Born Foundation to S. H. S., and the U.S. National Institutes of Health to R. D. (AI-082542) and S. N. J. M. (AI-068467). V. S. R. was supported in part by a training grant of the Ellison Medical Foundation to the Center for Tropical and Emerging Global Diseases.

## References


1. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. *Curr Pharm Des.* 2010; 16:2950–2960. [PubMed: 20722616]
2. Reszka AA, Rodan GA. *Mini-Rev Med Chem.* 2004; 4:711–717. [PubMed: 15379639]
3. Russell RGG, Rogers MJ. *Bone.* 1999; 25:97–106. [PubMed: 10423031]
4. Reszka AA, Rodan GA. *Curr Osteoporos Rep.* 2003; 1:45–52. [PubMed: 16036064]
5. Fleisch H, Russell RGG, Straumann F. *Nature.* 1966; 212:901–903. [PubMed: 4306793]
6. Fleisch H, Russell RGG, Francis MD. *Science.* 1969; 165:1262–1264. [PubMed: 5803538]
7. Francis MD, Russell RGG, Fleisch H. *Science.* 1969; 165:1264–1266. [PubMed: 4308521]
8. Urbina JA, Moreno B, Vierkotter S, Oldfield E, Payares G, Sanoja C, Bailey BN, Yan W, Scott DA, Moreno SNJ, Docampo R. *J Biol Chem.* 1999; 274:33609–33615. [PubMed: 10559249]
9. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. *J Bone Miner Res.* 1995; 10:1478–1487. [PubMed: 8686503]
10. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, Auriola S, Chilton KM, Russell RGG. *Bone.* 1999; 24:73S–79S. [PubMed: 10321934]
11. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RGG, Oppermann U. *Proc Natl Acad Sci.* 2006; 103:7829–7834. [PubMed: 16684881]
12. Hosfield DJ, Zhang Y, Dougan DR, Broun A, Tari LW, Swanson RV, Finn J. *J Biol Chem.* 2004; 279:8526–8529. [PubMed: 14672944]
13. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W. *ChemMedChem.* 2006; 1:267–273. [PubMed: 16892359]
14. Cheng F, Oldfield E. *J Med Chem.* 2004; 47:5149–5158. [PubMed: 15456258]
15. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. *J Pharmacol Exp Ther.* 2001; 296:235–242. [PubMed: 11160603]
16. Coxon FP, Thompson K, Rogers MJ. *Curr Op Pharmacol.* 2006; 6:307–312.
17. Sanders JM, Ghosh S, Chan JMW, Meints G, Wang H, Raker AM, Song Y, Colantino A, Burzynska A, Kafarski P, Morita CT, Oldfield E. *J Med Chem.* 2004; 47:375–384. [PubMed: 14711309]

18. Reddy R, Dietrich E, Lafontaine Y, Houghton TJ, Belanger O, Dubois A, Arhin FF, Sarmiento I, Fadhil I, Laquerre K, Ostiguy V, Lehoux D, Moeck G, Parr TR Jr, Rafai Far A. *ChemMedChem*. 2008; 3:1863–1868. [PubMed: 18973169]
19. Forlani G, Giberti S, Berlicki Ł, Petrollino D, Kafarski P. *J Agric Food Chem*. 2007; 55:4340–4347. [PubMed: 17474756]
20. Clézardin P, Massaia M. *Curr Pharm Des*. 2010; 16:3007–3014. [PubMed: 20722623]
21. Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R. *Angew Chem Int Ed*. 2009; 48:2949–2954.
22. Zhang Y, Cao R, Yin F, Hudock MP, Guo R–T, Krysiak K, Mukherjee S, Gao Y–G, Robinson H, Song Y, No JH, Kyle Bergan K, Leon A, Cass L, Goddard A, Chang T–K, Lin F–Y, Van Beek E, Papapoulos S, Wang AH–J, Kubo T, Ochi M, Mukkamala D, Oldfield E. *J Am Chem Soc*. 2009; 131:5153–5162. [PubMed: 19309137]
23. Coleman RE. *British J Cancer*. 2008; 98:1736–1740.
24. Roth AG, Drescher D, Yang Y, Redmer S, Uhlig S, Arenz C. *Angew Chem Int Ed*. 2009; 48:7560–7563.
25. Docampo R, Moreno SNJ. *Curr Pharm Des*. 2008; 14:882–888. [PubMed: 18473837]
26. Oldfield E. *Acc Chem Res*. 2010; 43:1216–1226. [PubMed: 20560544]
27. Ghosh S, Chan JMW, Lea CR, Meints GA, Lewis JC, Tovian ZS, Flessner RM, Loftus TC, Bruchhaus I, Kendrick H, Croft SL, Kemp RG, Kobayashi S, Nozaki T, Oldfield E. *J Med Chem*. 2004; 47:175–187. [PubMed: 14695831]
28. Martin MB, Grimley JS, Lewis JC, Heath HT III, Bailey BN, Kendrick H, Yardley V, Caldera A, Lira R, Urbina JA, Moreno SNJ, Docampo R, Croft SL, Oldfield E. *J Med Chem*. 2001; 44:909–916. [PubMed: 11300872]
29. Yardley V, Khan AA, Martin MB, Slifer TR, Araujo Fausto G, Moreno SNJ, Docampo R, Croft SL, Oldfield E. *Antimicrob Agents Chemother*. 2002; 46:929–931. [PubMed: 11850291]
30. Martin MB, Sanders JM, Kendrick H, De Luca-Fradley K, Lewis JC, Grimley JS, Van Brussel EM, Olsen JR, Meints GA, Burzynska A, Kafarski P, Croft SL, Oldfield E. *J Med Chem*. 2002; 45:2904–2914. [PubMed: 12086478]
31. Rosso VS, Szajnman SH, Malayil L, Galizzi M, Moreno SNJ, Docampo R, Rodriguez JB. *Bioorg Med Chem*. 2011; 19:2211–2217. [PubMed: 21419634]
32. Szajnman SH, García Liñares GE, Li Z–H, Galizzi M, Jiang C, Bontempi E, Ferella M, Moreno SNJ, Docampo R, Rodriguez JB. *Bioorg Med Chem*. 2008; 16:3283–3290. [PubMed: 18096393]
33. Szajnman SH, Bailey BN, Docampo R, Rodriguez JB. *Bioorg Med Chem Lett*. 2001; 11:789–792. [PubMed: 11277521]
34. Szajnman SH, Montalvetti A, Wang Y, Docampo R, Rodriguez JB. *Bioorg Med Chem Lett*. 2003; 13:3231–3235. [PubMed: 12951099]
35. Szajnman SH, Ravaschino EL, Docampo R, Rodriguez JB. *Bioorg Med Chem Lett*. 2005; 15:4685–4690. [PubMed: 16143525]
36. Ling Y, Sahota G, Odeh S, Chan JMW, Araujo FG, Moreno SNJ, Oldfield E. *J Med Chem*. 2005; 48:3130–3140. [PubMed: 15857119]
37. Bouzahzah B, Jelicks LA, Morris SA, Weiss LM, Tanowitz HB. *Parasitol Res*. 2005; 96:184–187. [PubMed: 15844009]
38. García Liñares G, Ravaschino EL, Rodriguez JB. *Curr Med Chem*. 2006; 13:335–360. [PubMed: 16475941]
39. Urbina JA, Docampo R. *Trends Parasitol*. 2003; 19:495–501. [PubMed: 14580960]
40. Brener Z. *Annu Rev Microbiol*. 1973; 27:347–382. [PubMed: 4201691]
41. Moreno SNJ, Li Z-H. *Expert Opinion Ther Targets*. 2008; 12:253–263.
42. Levine ND, Corliss JO, Cox FEG, Deroux G, Grain J, Honigberg BM, Leedale GF, Loeblich AR 3rd, Lom J, Lynn D, Merinfeld EG, Page FC, Poliansky G, Sprague V, Vavra J, Wallace FG. *J Protozool*. 1980; 27:37–58. [PubMed: 6989987]
43. Carruthers V, Boothroyd JC. *Curr Opin Microbiol*. 2007; 10:83–89. [PubMed: 16837236]
44. Fichera ME, Roos DS. *Nature*. 1997; 390:407–409. [PubMed: 9389481]


45. Stokkermans TJW, Schwartzman JD, Keenan K, Morrisette NS, Tilney LG, Roos DS. *Exp Parasitol.* 1996; 84:355–370. [PubMed: 8948325]
46. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, Milhous WK, Tzipori S, Ferguson DJ, Chakrabarti D, McLeod R. *Nature.* 1998; 393:801–805. [PubMed: 9655396]
47. Urbina JA. *Acta Tropica.* 2010; 115:55–68. [PubMed: 19900395]
48. Urbina JA. *Drugs Fut.* 2010; 35:409–420.
49. Amzel, LM. Personal communication.
50. Hosfield DJ, Zhang Y, Dougan DR, Broun A, Tari LW, Swanson R, Finn J. *J Biol Chem.* 2003; 278:18401–18407. [PubMed: 12621040]
51. Tarshis LC, Proteau PJ, Kellogg BA, Sacchetti JC, Poulter CD. *Proc Natl Acad Sci USA.* 1996; 93:15018–15023. [PubMed: 8986756]
52. Huang C-H, Gabelli SB, Oldfield E, Amzel ML. *Proteins.* 2010; 78:888–899. [PubMed: 19876942]
53. Cao R, Chen CK-M, Guo R-T, Wang AH, Oldfield E. *Proteins.* 2008; 73:431–439. [PubMed: 18442135]
54. Gabelli SB, McLellan JS, Montalvetti A, Oldfield E, Docampo R, Amzel ML. *Proteins.* 2006; 62:80–88. [PubMed: 16288456]
55. Van Beek E, Lowik C, Queans I, Papapoulos S. *J Bone Miner Res.* 1996; 11:1492–1497. [PubMed: 8889849]
56. Ebetino FH, Francis MD, Rogers MJ, Russell RGG. *Rev Contemp Pharmacother.* 1998; 9:233–243.
57. Jung A, Bisaz S, Fleisch H. *Calcif Tissue Res.* 1973; 11:269–280. [PubMed: 4350498]
58. Purser S, Moore PR, Swallow S, Gouverneur V. *Chem Soc Rev.* 2008; 37:320–330. [PubMed: 18197348]
59. Marma MS, Xia Z, Stewart C, Coxon F, Dunford JE, Baron R, Kashemirov BA, Ebetino FH, Triffitt JT, Russell RGG, McKenna CE. *J Med Chem.* 2007; 50:5967–5975. [PubMed: 17975902]
60. McKenna CE, Shen P-D. *J Org Chem.* 1981; 46:4573–4576.
61. Berkowitz DB, Bose M. *J Fluorine Chem.* 2001; 112:13–33.
62. Blackburn GM, England DA, Kolkmann F. *Chem Commun.* 1981:930–932.
63. Romanenko VD, Kukhar VP. *Chem Rev.* 2006; 106:3868–3935. [PubMed: 16967924]
64. De Schutter JW, Zaretsky S, Welbourn S, Pause A, Tsantrizos YS. *Bioorg Med Chem Lett.* 2010; 20:5781–5786. [PubMed: 20801032]
65. Lal GS. *J Org Chem.* 1993; 57:4676–4683.
66. Lal GS, Pez GP, Syvret RG. *Chem Rev.* 1996; 96:1737–1755. [PubMed: 11848809]
67. Xu Y, Qian YL, Prestwich GD. *Org Lett.* 2003; 5:2267–2270. [PubMed: 12816425]
68. Beier P, Opekar S, Mikhail Zibinsky M, Inessa Bychinskaya I, Prakash GKS. *Org Biomol Chem.* 2011; 9:4035–4038. [PubMed: 21526260]
69. Degenhardt CR, Burdsall DC. *J Org Chem.* 1986; 51:3488–3490.
70. Ling Y, Li Z-H, Miranda K, Oldfield E, Moreno SNJ. *J Biol Chem.* 2007; 282:30804–30816. [PubMed: 17724033]
71. The amino acid sequence of Proteins was obtained from the protein database from NCBI <http://www.ncbi.nlm.nih.gov/protein> (*T. cruzi*, 1YHK\_A; *T. brucei*, gi:30522953; *L. donovani*, gi:112363472; *T. gondii*, gi:108745448; Human, 2F7M\_F). Sequence alignments were created with ClustalX: Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ. *Trends Biochem Sciences.* 1998; 23:403–405.
72. Canavaci AM, Bustamante JM, Padilla AM, Perez Brandan CM, Simpson LJ, Xu D, Boehlke CL, Tarleton RL. *PLOS Negl Trop Dis.* 2010; 4:e740. [PubMed: 20644616]
73. Gubbels MJ, Li C, Striepen B. *Antimicrob Agents Chemother.* 2003; 43:309–316. [PubMed: 12499207]
74. Agrawal S, van Dooren GG, Beatty WL, Striepen B. *J Biol Chem.* 2009; 284:33683–33691. [PubMed: 19808683]

75. Ravaschino EL, Docampo R, Rodriguez JB. *J Med Chem.* 2006; 49:426–435. [PubMed: 16392828]
76. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R. *J Biol Chem.* 2001; 276:33930–33937. [PubMed: 11435429]
77. Montalvetti A, Fernandez A, Sanders JM, Ghosh S, Van Brussel E, Oldfield E, Docampo R. *J Biol Chem.* 2003; 278:17075–17083. [PubMed: 12618430]
78. Ogura K, Nishino T, Shinka T, Seto S. *Methods Enzymol.* 1985; 110:167–171.







**Scheme 1.**  
Isoprenoid biosynthesis in trypanosomatids and apicomplexan parasites.




**Scheme 2.**  
Reagents and Condition for the Preparation of the Title Compounds.



**Chart 1.**  
General formula and chemical structure of representative FDA-approved bisphosphonates clinically employed for different bone disorders.



- 7**,  $n = 5$ ;  $\text{R} = \text{OH}$   
**8**,  $n = 5$ ;  $\text{R} = \text{H}$   
**9**,  $n = 4$ ;  $\text{R} = \text{NH}_2$



- 10**,  $\text{R} = n\text{-hexyl}$   
**11**,  $\text{R} = n\text{-heptyl}$   
**12**,  $\text{R} = n\text{-dodecyl}$

**Chart 2.**  
Chemical structure of representative members of bisphosphonic acids derived from fatty acids.

Table 1

Comp	IC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)	IC <sub>50</sub> (μM)
	<i>Tc</i> FPPS	<i>Tg</i> FPPS	<i>T. cruzi</i> amastigotes	<i>T. gondii</i> tachyzoites
35	>1	>10	>10	>10
36	>1	>10	>10	>10
37	>1	>10	>10	>10
38	>1	>10	>10	>10
39	>1	3.42 ± 1.67	>10	>10
40	>1	0.160 ± 0.078	>10	>10
41	>1	0.241 ± 0.120	>10	>10
42	>1	0.616 ± 0.259	>10	>10
43	>1	0.035 ± 0.019	13% at 10 μM	2.67
44	>1	0.060 ± 0.006	>10	>10
Risedronate	0.027 ± 0.003	0.074 ± 0.017	-	
benznidazole	-		2.768 ± 0.488	